Multidrug-resistant Gram-negative bacterial infections: Are you ready for the challenge?

Current Clinical Pharmacology

Volumn 9, Issue 1, 2014, Pages 27-38

  Curcio, Daniel ^a  

^a Hospital Municipal Chivilcoy   (Argentina)

Author keywords

Carbapenems; Cephalosporins; Gram negative; Multidrug resistance; Tigecycline; lactamases inhibitors

Indexed keywords

6 (5,6 DIHYDRO 8H IMIDAZO[2,1 C][1,4]OXAZIN 2 YLMETHYLENE) 7 OXO 4 THIA 1 AZABICYCLO[3.2.0]HEPT 2 ENE 2 CARBOXYLIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AVIBACTAM; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; BIAPENEM; CARBAPENEM DERIVATIVE; CEFALOTIN; CEFEPIME; CEFOTAXIME; CEFTAROLINE; CEFTAZIDIME; CEFTOBIPROLE; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN DERIVATIVE; CLOXACILLIN; DORIPENEM; EXTENDED SPECTRUM BETA LACTAMASE; FSI 1686; ME 1071; PANIPENEM; PENICILLIN DERIVATIVE; PIPERACILLIN; RO 481220; TIGECYCLINE; TOMOPENEM; TONOPENEM; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BLOODSTREAM INFECTION; CLASSIFICATION; DRUG EFFICACY; DRUG POTENCY; ENTEROBACTER; ENTEROBACTERIACEAE; EPIDEMIOLOGICAL DATA; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HUMAN; KLEBSIELLA PNEUMONIAE; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; REVIEW; SERRATIA MARCESCENS; SURGICAL INFECTION; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84894069648     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/15748847113089990062     Document Type: Review

References (125)

1. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008; 197: 1079-81.
2. Livermore DM. Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-584.
3. Ambler RP, Coulson AF, Frere JM, et al. A standard numbering scheme for the class A beta-lactamases. Biochem J 1991; 276(Pt 1): 269-70.
4. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211-33.
5. Pitout JDD, Laupland KB. Extended-spectrum β-lactamaseproducing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8: 159-66.
6. Pfeifer Y, Cullik A, Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int J Med Microbiol 2010; 300: 371-79.
7. Livermore DM, Canton R, Gniadkowski M, et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59: 165-74.
8. Hanson ND. AmpC beta-lactamases: what do we need to know for the future? J Antimicrob Chemother 2003; 52: 2-4.
9. Livermore DM. Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods. Eur J Clin Microbiol1987; 6: 439-45.
10. Livermore DM, Yang YJ. β-Lactamase lability and inducer power of newer β-lactam antibiotics in relation to their activity against β-lactamase-inducibility mutants of Pseudomonas aeruginosa. J Infect Dis1987; 155: 775-82.
11. Stapleton P, Shannon K, Phillips I. The ability of β-lactam antibiotics to select mutants with derepressed β-lactamase synthesis from Citrobacter freundii. J Antimicrob Chemother 1995; 36: 483-96.
12. Weber DA, Sanders CC. Diverse potential of β-lactamase inhibitors to induce class I enzymes. Antimicrob Agents Chemother 1990; 34: 156-8.
13. Kitzis MD, Ferre B, Coutrot A, Acar JF, Gutmann L. In vitro activity of combinations of beta-lactam antibiotics with betalactamase inhibitors against cephalosporinase-producing bacteria. Eur J Clin Microbiol Infect Dis 1989; 8: 783-8.
14. Curcio D. On behaf of the Latin American antibiotic use in intensive care unit group. Antibiotic prescription in intensive care units in Latin America. Rev Argent Microbiol 2011; 43: 203-11.
15. Queenan AM, Bush K. Carbapenemases: the versatile b-lactamases. Clin Microbiol Rev 2007; 20: 440-58.
16. Bradford PA, Urban C, Mariano N, Projan SJ, Rahal JJ, Bush K. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC blactamase, and the foss of an outer membrane protein. Antimicrob Agents Chemother 1997; 41: 563-9.
17. Nordmann P, Mariotte S, Naas T, Labia R, Nicolas MH. Biochemical properties of a carbapenem-hydrolyzing b-lactamase from Enterobacter cloacae and cloning of the gene into Escherichia coli. Antimicrob Agents Chemother 1994; 37: 939-46.
18. Rasmussen BA, Bush K, Keeney D, et al. Characterization of IMI-1 b-lactamase, a class A carbapenem-hydrolyzing enzyme from Enterobacter cloacae. Antimicrob Agents Chemother 1996; 40: 2080-6.
19. Poirel L, Le Thomas I, Naas T, Karim A, Nordmann P. Biochemical sequence analyses of GES-1, a novel class A extended-spectrum b-lactamase, and the class 1 integron In52 from Klebsiella pneumoniae. Antimicrob Agents Chemother 2000; 44: 622-32.
20. Castanheira M, Mendes RE, Walsh TR, Gales AC, Jones RN. Emergence of the extended-spectrum b-lactamase GES-1 in a Pseudomonas aeruginosa strain from Brazil: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2004; 48: 2344-5.
21. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemase (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010; 65: 1119-25.
22. Bratu S, Mooty M, Nichani S, et al. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob Agents Chemother 2005; 49: 3018-20.
23. Kitchel B, Rasheed JK, Endimiani A, et al. Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2010; 54: 4201-7.
24. Noordman P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009; 9: 228-36.
25. Grundmann H, Livermore DM, Giske CG, et al. CNSE Working Group. Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill 2012; 15: pii 19711.
26. Nordmann P, Naas T, Poirel L. Global spread of Carbapenemaseproducing Enterobacteriaceae. Emerg Infect Dis 2011; 17: 1791-8.
27. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 9: 597-602.
28. Pitout JDD, Gregson DB, Poirel L, McClure JA, Le P, Church DL. Detection of Pseudomonas aeruginosa producing metallo-_-lactamases in a large centralized laboratory. J Clin Microbiol 2005; 43: 3129-35.
29. Yan JJ, Ko WC, Tsai SH, Wu HM, Wu JJ. Outbreak of infection with multidrugresistant Klebsiella pneumoniae carrying blaIMP-8 in a university medical center in Taiwan. J Clin Microbiol 2001; 39: 4433-9.
30. Lee K, Lee WG, Uh Y, Ha GY, Cho J, Chong Y. Korean Nationwide Surveillance of Antimicrobial Resistance Group. VIMand IMP-type metallo-β-lactamase-producing Pseudomonas spp. and Acinetobacter spp. in Korean hospitals. Emerg Infect Dis 2003; 9: 868-71.
31. Sader HS, Castanheira M, Mendes RE, Toleman M, Walsh TR, Jones RN. Dissemination and diversity of metallo-_-lactamases in Latin America: report from the SENTRY Antimicrobial Surveillance Program. Int J Antimicrob Agents 2004; 25: 57-71.
32. Deshpande LM, Jones RN, Fritsche TR, Sader HS. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRYAntimicrobial Surveillance Program (2000-2004). Microb Drug Resist 2006; 12: 223-30.
33. Souli M, Kontopidou FV, Papadomichelakis E, Galani I, Armaganidis A, Giamarellou H. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallobeta-lactamase in a Greek University Hospital. Clin Infect Dis 2008; 46: 847-54.
34. Yildirim I, Ceyhan M, Gur D, Mugnaioli C, Rossolini GM. First detection of VIM-1 type metallo-betalactamase in a multidrugresistant Klebsiella pneumoniae clinical isolate from Turkey also producing the CTX-M-15 extended-spectrum betalactamase. J Chemother 2007; 19: 467-8.
35. Galani I, Souli M, Koratzanis E, Koratzanis G, Chryssouli Z, Giamarellou H. Emerging bacterial pathogens: Escherichia coli, Enterobacter aerogenes and Proteus mirabilis clinical isolates harbouring the same transferable plasmid coding for metallo-betalactamase VIM-1 in Greece. J Antimicrob Chemother 2007; 59: 578-9.
36. Tsakris A, Ikonomidis A, Poulou A, Spanakis N, Pournaras S, Markou F. Transmission in the community of clonal Proteus mirabilis carrying VIM-1 metallo-beta-lactamase. J Antimicrob Chemother 2007; 60: 136-9.
37. Miriagou V, Tzouvelekis LS, Flevari K, Tsakiri M, Douzinas EE. Providencia stuartii with VIM-1 metallo-beta-lactamase. J Antimicrob Chemother 2007; 60: 183-4.
38. Health Protection Agency. National Resistance Alert: Carbapenemases in Enterobacteriaceae. Health Protection Report 2009; 3: news.
39. Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimirob Agents Chemother 2009; 53: 5046-54.
40. Grundmann H, Livermore DM, Giske CG, et al. CNSE Working Group. Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill 2010; 15: pii. 19711.
41. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51: 3471-3484.
42. Bertini A, Poirel L, Bernabeu S, et al. Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51: 2324-8.
43. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008; 46: 1254-63.
44. Hidron AI, Edwards JR, Patel J, et al. National Healthcare Safety Network Team; Participating National Healthcare Safety Network Facilities. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29: 996-1011.
45. Hirsch EB, Tam VH. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res 2010; 10: 441-51.
46. Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 2001; 119(2 Suppl): 397S-404S.
47. Struelens MJ, Monnet DL, Magiorakos AP, Santos O'Connor F, Giesecke J. European NDM-1 Survey Participants. New Delhi metallo-beta-lactamase 1-producing Enterobacteriaceae: emergence and response in Europe. Euro Surveill. 2010; 15: pii. 19716.
48. Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). Diagn Microbiol Infect Dis 2012; 73(4): 354-60.
49. TEST progam [homepage on the Internet]. Available from: http://www.testsurveillance.com (last access January 7, 2009).
50. Pfaller MA, Jones RN. MYSTIC Study Group (Europe). Antimicrobial susceptibility of inducible AmpC beta-lactamaseproducing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000. Int J Antimicrob Agents 2002; 19: 383-8.
51. Nordmann P, Naas T, Poirel L. Global spread of Carbapenemaseproducing Enterobacteriaceae. Emerging Infect Dis 2011; 17: 1791-8.
52. Castanheira M, Deshpande LM, Mathai D, Bell JM, Jones RN, Mendes RE. Early dissemination of NDM-1-and OXA-181-producing Enterobacteriaceae in Indian hospitals: report from the SENTRY Antimicrobial Surveillance Program, 2006-2007. Antimicrob Agents Chemother 2011; 55: 1274-8.
53. Cuzon G, Naas T, Villegas MV, Correa A, Quinn JP, Nordmann P. Wide dissemination of Pseudomonas aeruginosa producing betalactamase blaKPC-2 gene in Colombia. Antimicrob Agents Chemother 2011; 55: 5350-3.
54. Beirão EM, Furtado JJ, Girardello R, Ferreira FH, Gales AC. Clinical and microbiological characterization of KPC-producing Klebsiella pneumoniae infections in Brazil. Braz J Infect Dis 2011; 15: 69-73.
55. Gomez SA, Pasteran FG, Faccone D, et al. Clonal dissemination of Klebsiella pneumoniae ST258 harbouring KPC-2 in Argentina. Clin Microbiol Infect 2011; 17: 1520-4.
56. Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase-and metallobeta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2008; 52: 570-3.
57. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century: a clinical super-challenge. N Engl J Med 2009; 360: 439-43.
58. Boucher HW, Talbot GH, Bradley JS, et al. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
59. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005; 18: 657-86.
60. Sader HS, Hsiung A, Fritsche TR, Jones RN. Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype. Diagn Microbiol Infect Dis 2007; 57: 341-4.
61. Blosser R. Susceptibility Testing of Doripenem against 815 Grampositive and Gram-negative Clinical Isolates (DORI-M-004). Herndon, VA, USA; 2003. Focus Technologies Inc. (project number 1343-102).
62. Evangelista A, Yee YC, Pillar C, et al. Surveillance of doripenem activity against clinical isolates collected worldwide (2003) (DORI-M-2008). Abstracts of the Forty-fifth Annual Meeting of Infectious Disease Society of America; 2007; San Diego, CA. Chicago, IL, USA: Infectious Disease Society of America; p. 159. Abstract 523.
63. Mushtaq S, Ge Y, Livermore DM. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases. Antimicrob Agents Chemother 2004; 48: 1313-9.
64. Traczewski MM, Brown SD. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob Agents Chemother 2006; 50: 819-21.
65. Jones RN, Huynh HK, Biedenbach DJ, et al. Doripenem (S-4661), a novel carbapenem: comparative activity against con-temporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother 2004; 54: 144-54.
66. Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 2004; 48: 3136-40.
67. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008; 36: 1089-96.
68. Réa-Neto A, Niederman M, Lobo SM, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008; 24: 2113-26.
69. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. Antimicrob Agents Chemother 2008; 52: 761-6.
70. Doribax (doripenem) [package insert]. Raritan, NJ: Ortho-McNeilPharmaceuticals; 2009.
71. Ubukata K, Chiba N, Kobayashi R. Comparison of in vitro activity of biapenem with other antimicrobial agents against clinical isolates of Pseudomonas aeruginosa. Chemother Jpn 2002; 50: 1-10.
72. Matsumoto F, Inoue M, Sakurai I. A comparative study of biapenem and imipenem/cilastatin in lower respiratory infections. Jpn J Chemother 2000; 48: 45-67.
73. Matsumoto F, Imai T, Sakurai I. A comparative study of biapenem and imipenem/cilastatin for bacterial pneumonia. Jpn J Chemother 1995; 43: 41-62.
74. Yamada K, Yamamoto Y, Yanagihara K, et al. In vivo efficacy and pharmacokinetics of biapenem in a murine model of ventilatorassociated pneumonia with Pseudomonas aeruginosa. J Infect Chemother 2012.
75. Takata T, Aizawa K, Shimizu A, Sakakibara S, Watabe H, Totsuka K. Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis. J Infect Chemother 2004; 10: 76-85.
76. Goa KL, Noble S. Panipenem/betamipron. Drugs 2003; 63: 913-25.
77. Shimada J, Kawahara Y. Overview of a new carbapenem, panipenem/betamipron. Drugs Exp Clin Res 1994; 20: 241-5.
78. Goto H, Inamatsu T, Sano Y, Shimada K. Evaluation of a multihospital cooperative study on the efficacy and safety of panipenem/betamipron (PAPM/BP) on elderly patients of respiratory infections. Kansenshogaku Zasshi 1999; 73: 43-52.
79. Kwon KT, Cheong HS, Rhee JY, et al. Panipenem versus cefepime as empirical monotherapy in adult cancer patients with febrile neutropenia: a prospective randomized trial. Jpn J Clin Oncol 2008; 38: 49-55.
80. Mallalieu NL, Lennon S, Liu M, et al. Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem. Antimicrob Agents Chemother 2008; 52: 2360-6.
81. Sugihara K, Tateda K, Yamamura N, Koga T, Sugihara C, Yamaguchi K. Efficacy of human-simulated exposures of tomopenem (formerly CS-023) in a murine model of Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2011; 55: 5004-9.
82. Morinaga Y, Yanagihara K, Nakamura S, et al. In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model. J Antimicrob Chemother 2008; 62: 1326-31.
83. Koga T, Masuda N, Kakuta M, Namba E, Sugihara C, Fukuoka T. Potent in vitro activity of tomopenem (CS-023) against methicillinresistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008; 52: 2849-54.
84. Kim D, Joo H, Liu S, Mao S, Choi W. FSI-1686, a Novel β-Methylcarbapenem: Synthesis and Structure-Activity Relationships (SAR). Abstracts of the 51th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011; Chicago, IL, USA: American Society for Microbiology; Abstract F1-141.
85. Joo H, Kim D, Kowalik E, et al. FSI-1686, a Novel β-Methylcarbapenem; In Vitro Activity Against Carbapenem-Resistance Gram-Negative Bacteria. Abstracts of the 51th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011; Chicago, IL, USA: American Society for Microbiology; Abstract F1-142.
86. Joo H, Kim D, Kowalik E, et al. Efficacy of FSI-1686 in Animal Model of Carbapenem-Resistance Gram-Negative Bacterial Infection. Abstracts of the 51th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011; Chicago, IL, USA: American Society for Microbiology; Abstract F1-143.
87. Kanafani ZA, Corey GR. Ceftaroline: a cephalosporin with expanded Grampositive activity. Future Microbiol 2009; 4: 25-33.
88. Sader HS, Fritsche TR, Kaniga K, Ge Y, Jones RN. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collectionof clinical strains. Antimicrob Agents Chemother 2005; 49: 3501-12.
89. Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore DM. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007; 60: 300-11.
90. Ge Y, Biek D, Talbot GH, Sahm DF. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother 2008; 52: 3398-407.
91. Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in the treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007; 51: 3612-6.
92. Ge Y, Floren L, Redman R, et al. Single-dose pharmacokinetics (PK) of ceftaroline (PPI-0903) in healthy subjects. Abstracts of the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006; San Francisco, CA, USA: American Society for Microbiology; Abstract A-1936.
93. Jacqueline C, Caillon J, Miegeville A. Penetration of ceftaroline (PPI-0903), a newcephalosporin, into lung tissues: measurement of plasma and lung tissue concentrations after a short IV infusion in the rabbit. Abstracts of the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006; San Francisco, CA, USA: American Society for Microbiology; Abstract A-1938.
94. Anderson SD, Gums JG. Ceftobiprole: an extended-spectrum antimethicillinresistant Staphylococcus aureus cephalosporin. Ann Pharmacother 2008; 42: 806-16.
95. Fritsche TR, Sader HS, Jones RN. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY antimicrobial surveillance program (2005-2006). Diagn Microbiol Infect Dis 2008; 61: 86-95.
96. Hebeisen P, Heinze-Krauss I, Angehrn P, Hohl P, Page MG, Then RL. In vitro and in vivo properties of Ro-63-9141, a novel broadspectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother 2001; 45: 825-36.
97. Queenan AM, Shang W, Kania M. Interactions of ceftobiprole with ß-lactamases from molecular classes A to D. Antimicrob Agents Chemother 2007; 51: 3089-95.
98. Livermore DM, Hope R, Brick G, Lillie M, Reynolds R. BSAC Working Parties on Resistance Surveillance. Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 2008; 62: ii41-51.
99. Livermore DM, Hope R, Brick G, Lillie M, Reynolds R. BSAC Working Parties on Resistance Surveillance. Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 2008; 62: ii55-63.
100. Murthy B, Schmitt-Hoffmann A. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin Pharmacokinet 2008; 47: 21-33.
101. Lodise TP Jr, Pypstra R, Kahn JB, et al. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob Agents Chemother 2007; 51: 2378-87.
102. Pankey GA. Tigecycline. J Antimicrob Chemother 2005; 56: 470-80.
103. Souli M, Kontopidou FV, Koratzanis E, et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals. Antimicrob Agents Chemother 2006; 50: 3166-9.
104. Food and Drug Administration [homepage on the Internet] Available from: http://www.accessdata.fda.gov/drugsatfda_docs/ label/ [last access June 20, 2009].
105. Curcio D, Fernández F, Duret F. Initial use of tigecycline in Argentina. Rev Chilena Infectol 2007; 24: 497-9.
106. Curcio D, Fernández F, Cané A, Barcelona L, Stamboulian D. Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry. Braz J Infect Dis 2008; 12: 198-201.
107. Freire AT, Melnyk V, Kim MJ, et al. 311 Study Group. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010; 68: 140-51.
108. Curcio D, Fernández F, Vergara J, Vazquez W, Luna CM. Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline. J Chemother 2009; 21: 58-62.
109. Curcio D, Castagnino J, Vazquez W, Vergara G, Curiale A. Latin American Tigecycline Use Registry for Ventilator Associated Pneumonia (LatinVAP). Tigecycline in the treatment of ventilatorassociated pneumonia: experience from the Latin American Tigecycline Use Registry. Infez Med 2010; 18: 27-34.
110. Scaglione F. Comment on: Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011; 66: 2892-3; author reply 2895-6.
111. Burkhardt O, Rauch K, Kaever V, Hadem J, Kielstein JT, Welte T. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agents 2009; 34: 101-2.
112. Peleg AY, Potoski BA, Rea R, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007; 59: 128-31.
113. Curcio D. Off-label use of antibiotics in intensive care unit: the multidrug-resistant pathogens challenge. J Crit Care 2011; 26: 95-6.
114. Weiss WJ, Petersen PJ, Murphy TM, et al. In vitro and in vivo activities of novel 6-methylidene penems as beta-lactamase inhibitors. Antimicrob Agents Chemother 2004; 48: 4589-96.
115. Petersen PJ, Jones CH, Venkatesan AM, Mansour TS, Projan SJ, Bradford PA. Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. Antimicrob Agents Chemother 2009; 53: 370-84.
116. Petersen PJ, Jones CH, Venkatesan AM, Bradford PA. Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. Antimicrob Agents Chemother 2009; 53: 1698-700.
117. Richter HG, Angehrn P, Hubschwerlen C, et al. Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases. J Med Chem 1996; 39: 3712-22.
118. Jones RN, Johnson DM. Comparative in vitro activity of apalcillin alone and combined with Ro 48-1220, a novel penam betalactamase inhibitor. Clin Microbiol Infect 1995; 1: 86-100.
119. Tzouvelekis LS, Gazouli M, Prinarakis EE, Tzelepi E, Legakis NJ. Comparative evaluation of the inhibitory activities of the novel penicillanic acid sulfone Ro 48-1220 against beta-lactamases that belong to groups 1, 2b, and 2be. Antimicrob Agents Chemother 1997; 41: 475-7.
120. Ishii Y, Eto M, Mano Y, Tateda K, Yamaguchi K. In vitro potentiation of carbapenems with ME1071, a novel metallo-betalactamase inhibitor, against metallo-beta-lactamase-producing Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2010; 54: 3625-9.
121. Hope R, Mushtaq S, Morinaka A, Ishihama T, Maebashi K, Livermore D. Protection of Carbapenems by ME1071 Against Metallo-β-Lactamase-Producing Enterobacteriaceae Including Those with NDM Enzyme. Abstracts of the 51th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011; Chicago, IL, USA: American Society for Microbiology; Abstract F1-150.
122. Livermore DM, Mushtaq S, Warner M, Miossec C, Woodford N. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum b-lactamases and carbapenemases. J Antimicrob Chemother 2008; 62: 1053-6.
123. Endimiani A, Choudhary Y, Bonomo RA. In vitro activity of NXL104 in combination with b-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother 2009; 53: 3599-601.
124. Mushtaq S, Warner M, Livermore DM. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. J Antimicrob Chemother 2010; 65: 2376-81.
125. Clinical Trials Gov. [homepage on the Internet]. Available from: http://www.clinicaltrials.gov/ct2/results? term=NXL104 [last access July 9; 2012].